Equities analysts forecast that Kindred Biosciences, Inc. (NASDAQ:KIN) will post earnings per share (EPS) of ($0.29) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kindred Biosciences’ earnings. Kindred Biosciences reported earnings per share of ($0.25) in the same quarter last year, which suggests a negative year-over-year growth rate of 16%. The company is expected to issue its next earnings results on Monday, August 14th.

On average, analysts expect that Kindred Biosciences will report full-year earnings of ($1.33) per share for the current financial year, with EPS estimates ranging from ($1.40) to ($1.26). For the next year, analysts anticipate that the firm will post earnings of ($1.08) per share, with EPS estimates ranging from ($1.10) to ($1.05). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Kindred Biosciences.

Kindred Biosciences (NASDAQ:KIN) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.04.

Several research firms recently issued reports on KIN. BMO Capital Markets reiterated a “hold” rating and set a $8.00 price target on shares of Kindred Biosciences in a research report on Friday, May 5th. Zacks Investment Research upgraded shares of Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research report on Tuesday, June 20th. ValuEngine upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. FBR & Co restated a “buy” rating on shares of Kindred Biosciences in a research report on Wednesday, May 31st. Finally, Aegis began coverage on shares of Kindred Biosciences in a research report on Friday, June 16th. They issued a “buy” rating and a $10.50 target price on the stock. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Kindred Biosciences presently has an average rating of “Buy” and an average target price of $8.80.

TRADEMARK VIOLATION WARNING: “Kindred Biosciences, Inc. (NASDAQ:KIN) Expected to Post Earnings of -$0.29 Per Share” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/11/kindred-biosciences-inc-nasdaqkin-expected-to-post-earnings-of-0-29-per-share.html.

Kindred Biosciences (KIN) traded down 6.47% on Tuesday, reaching $7.95. 141,630 shares of the company traded hands. The stock has a 50-day moving average of $7.25 and a 200 day moving average of $6.51. The company’s market capitalization is $185.31 million. Kindred Biosciences has a 52-week low of $3.53 and a 52-week high of $9.65.

In other Kindred Biosciences news, insider Richard Chin sold 13,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $8.26, for a total value of $107,380.00. Following the sale, the insider now owns 2,297,546 shares in the company, valued at $18,977,729.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Park West Asset Management Llc bought 155,076 shares of the business’s stock in a transaction on Thursday, May 11th. The stock was bought at an average price of $6.83 per share, for a total transaction of $1,059,169.08. The disclosure for this purchase can be found here. Company insiders own 19.10% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN increased its position in Kindred Biosciences by 1.1% in the first quarter. Wells Fargo & Company MN now owns 329,902 shares of the biopharmaceutical company’s stock valued at $2,326,000 after buying an additional 3,550 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Kindred Biosciences by 28.5% in the first quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 4,954 shares during the last quarter. Acadian Asset Management LLC increased its position in Kindred Biosciences by 51.6% in the first quarter. Acadian Asset Management LLC now owns 29,759 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 10,134 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Kindred Biosciences during the first quarter valued at about $102,000. Finally, Renaissance Technologies LLC increased its position in Kindred Biosciences by 6.0% in the fourth quarter. Renaissance Technologies LLC now owns 351,600 shares of the biopharmaceutical company’s stock valued at $1,494,000 after buying an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 60.94% of the company’s stock.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.